View by Specialty

Trending

PC0924Price_Graphic_01_WEB
September 17, 2024
2 min read
Save

Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents

Gastrointestinal Cancer News

SPONSORED CONTENT
Save
SPONSORED CONTENT
June 13, 2023
3 min read
Save

FDA news: License applications accepted for melanoma, endometrial cancer therapies

FDA news: License applications accepted for melanoma, endometrial cancer therapies

The FDA announced several regulatory actions the past few weeks.

SPONSORED CONTENT
June 12, 2023
2 min read
Save

Immunomodulators heighten risk for high-grade cervical neoplasia, cancer in women with IBD

Immunomodulators heighten risk for high-grade cervical neoplasia, cancer in women with IBD

Cumulative exposure to immunomodulators increased the risk for high-grade cervical intraepithelial neoplasia and cervical cancer in women with inflammatory bowel disease, according to data from Alimentary Pharmacology & Therapeutics.

Trending

PC0924Price_Graphic_01_WEB
September 17, 2024
2 min read
Save

Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents

SPONSORED CONTENT
June 09, 2023
2 min read
Save

Novel AhR inhibitor shows tolerability, activity in advanced solid tumors

Novel AhR inhibitor shows tolerability, activity in advanced solid tumors

CHICAGO — A novel oral aryl hydrocarbon receptor inhibitor appeared well tolerated and safe among a small cohort of patients with advanced solid tumors, according to phase 1 study results presented at ASCO Annual Meeting.

SPONSORED CONTENT
June 07, 2023
2 min read
Save

NALIRIFOX extends OS, PFS for certain patients with pancreatic cancer

NALIRIFOX extends OS, PFS for certain patients with pancreatic cancer

CHICAGO — First-line NALIRIFOX significantly extended in OS and PFS vs. gemcitabine and nab-paclitaxel among patients with treatment-naive metastatic pancreatic ductal adenocarcinoma, according to a study presented at ASCO Annual Meeting.

SPONSORED CONTENT
June 07, 2023
2 min read
Save

Tumor mutational burden associated with survival on immunotherapy across cancer types

Tumor mutational burden associated with survival on immunotherapy across cancer types

CHICAGO — Higher tumor mutational burden appeared associated with more favorable real-world OS among a large cohort of patients with various cancer types who used immune checkpoint inhibitor monotherapy.

SPONSORED CONTENT
June 05, 2023
1 min read
Save

Hormone replacement therapy increases risk for GI cancers in postmenopausal women

Hormone replacement therapy increases risk for GI cancers in postmenopausal women

CHICAGO — The odds of having gastric and pancreatic cancers were higher among postmenopausal women on hormone replacement therapy and remained significant after controlling for risk factors, according to data at Digestive Disease Week.

SPONSORED CONTENT
June 05, 2023
3 min read
Save

Trastuzumab deruxtecan shows ‘broad activity’ in HER2-expressing solid tumors

Trastuzumab deruxtecan shows ‘broad activity’ in HER2-expressing solid tumors

CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.

SPONSORED CONTENT
June 04, 2023
3 min read
Save

Neoadjuvant chemotherapy regimen shows durable survival benefit in rectal cancer

Neoadjuvant chemotherapy regimen shows durable survival benefit in rectal cancer

CHICAGO — Administering modified FOLFIRINOX chemotherapy before chemoradiation, surgery and adjuvant chemotherapy improved survival outcomes of patients with locally advanced rectal cancer, according to results of the PRODIGE 23 trial.

SPONSORED CONTENT
June 04, 2023
2 min read
Save

Some patients with locally advanced rectal cancer can be spared pelvic radiation

Some patients with locally advanced rectal cancer can be spared pelvic radiation

CHICAGO — Most patients with intermediate-risk rectal cancer can undergo curative-intent treatment without the need for pelvic radiation, according to study results presented during a press conference at ASCO Annual Meeting.

SPONSORED CONTENT
June 04, 2023
6 min read
Save

Healio | HemOncToday announce 2023 Disruptive Innovators at ASCO

Healio | HemOncToday announce 2023 Disruptive Innovators at ASCO

CHICAGO — During ASCO Annual Meeting, Healio honored our Healio Disruptive Innovators in hematology/oncology in our second annual award ceremony.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails